Survodutide: What the Phase 3 Data Show and When It Might Be Available

What survodutide is and how it works

Survodutide (development code BI 456906) is an investigational injectable being developed by Boehringer Ingelheim in partnership with Zealand Pharma, which originated the molecule. It is given as a once-weekly injection under the skin.

Unlike semaglutide (Wegovy, Ozempic), which acts on a single receptor, survodutide is a dual agonist: it activates both the GLP-1 receptor and the glucagon receptor. The GLP-1 arm curbs appetite and slows gastric emptying, the same pathway used by existing weight-loss drugs. The glucagon arm is the point of differentiation — it is associated with increased energy expenditure and, importantly, with direct effects on the liver that reduce hepatic fat. This is the biological rationale behind studying survodutide not only for obesity but also for metabolic dysfunction-associated steatohepatitis (MASH), a serious fatty liver disease.

Survodutide has not been approved by any regulatory agency. Its safety and efficacy have not been established, and it cannot be prescribed or legally purchased as of July 2026.

Phase 3 obesity results: SYNCHRONIZE-1

The lead obesity trial, SYNCHRONIZE-1 (NCT06066515), was a Phase 3, double-blind, placebo-controlled study of 725 adults living with obesity or overweight who did not have type 2 diabetes. Participants received once-weekly survodutide at 3.6 mg or 6.0 mg, or placebo, for 76 weeks alongside lifestyle counseling. Boehringer Ingelheim and Zealand Pharma reported positive topline results on April 28, 2026, and the full data were presented at the American Diabetes Association (ADA) Scientific Sessions in June 2026 and published simultaneously in the New England Journal of Medicine on June 7, 2026.

How much weight participants lost depends on which statistical estimand is quoted. Using the efficacy estimand (which reflects results while people stayed on treatment), survodutide produced mean weight loss of up to 16.6% at 76 weeks versus 3.2% for placebo, an absolute reduction of up to about 39.2 lb (17.8 kg). Using the more conservative intention-to-treat / treatment-regimen estimand (which counts everyone regardless of whether they stopped), the reductions were −13.0% at the 6.0 mg dose and −12.2% at 3.6 mg, versus −5.4% for placebo. Both comparisons were statistically significant (p<0.001).

On the responder endpoint, 72.6% (3.6 mg) and 71.9% (6.0 mg) of participants lost at least 5% of body weight in the ITT analysis, versus 46.3% on placebo; under the efficacy estimand this reached up to 85.1% versus 38.8%. An MRI substudy found the weight loss was driven predominantly by fat rather than muscle, with liver-fat reductions of up to 63.1% and visceral-fat reductions of up to 34% at the highest dose. Gastrointestinal side effects were the most common adverse events, generally mild to moderate and temporary, and discontinuations were more frequent during dose escalation — a pattern typical of the GLP-1 class.

The liver-disease angle: SYNCHRONIZE-MASLD and the MASH program

Survodutide's liver effects are studied directly in a separate set of trials. SYNCHRONIZE-MASLD (NCT06309992) enrolled 216 adults with obesity and at-risk MASLD and treated them for 48 weeks, randomized 2:1 to once-weekly survodutide 6.0 mg or placebo. Published in Nature Medicine on June 7, 2026, it met both co-primary endpoints: 84.2% of the survodutide group achieved a ≥30% reduction in liver fat (measured by MRI-PDFF) versus 24.3% on placebo under the efficacy estimand, and liver fat was normalized (<5%) in about 61% of treated participants.

The higher-stakes MASH question is being tested in two large Phase 3 outcome trials, LIVERAGE (about 1,800 adults with MASH and F2–F3 fibrosis) and LIVERAGE-Cirrhosis (about 1,590 adults with compensated MASH cirrhosis). These were initiated in 2024. As of July 2026 they are ongoing and have not produced a Phase 3 MASH readout. Any claims about survodutide resolving MASH at this stage rest on earlier Phase 2b data, not confirmatory Phase 3 evidence.

The U.S. FDA granted survodutide Breakthrough Therapy designation for non-cirrhotic MASH with moderate or advanced fibrosis in September 2024 (announced October 8, 2024), on top of a Fast Track designation granted in May 2021; the EMA accepted it into its PRIME scheme in November 2023. These designations can speed development and review but do not guarantee approval.

How survodutide compares to tirzepatide and semaglutide

There is no head-to-head trial comparing survodutide with tirzepatide (Zepbound/Mounjaro) or semaglutide (Wegovy/Ozempic), so any comparison is cross-trial and imperfect: the studies enrolled different populations and used different designs and estimands. With that caveat, the approximate benchmarks are useful for context.

On mean weight loss, survodutide's up-to-16.6% (efficacy estimand) or ~13% (ITT) in SYNCHRONIZE-1 sits below tirzepatide, which produced about 20.9% at the 15 mg dose over 72 weeks in SURMOUNT-1 (treatment-regimen estimand). It lands close to semaglutide 2.4 mg, which produced about 14.9% over 68 weeks in STEP 1. Both tirzepatide and semaglutide are already FDA-approved and available; survodutide is not.

Where survodutide aims to differentiate is not raw pounds lost but its glucagon-driven metabolic and liver effects. Its most distinctive data are the large liver-fat reductions and its dedicated MASH program — an area where the dual mechanism may offer something the GLP-1-only and GLP-1/GIP drugs have not yet demonstrated in Phase 3 outcome trials. Whether that translates into an approved advantage depends on the LIVERAGE results, which are still pending.

What this means for patients right now

Survodutide is not available. It is an investigational drug that has not been approved by the FDA, the EMA, or any other regulator, and Boehringer Ingelheim has not announced a filing to any agency as of July 2026. You cannot get a legitimate prescription for it, and it is not sold through any pharmacy.

Be especially cautious about any website, telehealth service, or 'peptide' vendor offering survodutide for sale. Because the drug is investigational, there is no FDA-approved version and no legally compounded version — any product marketed as survodutide outside a clinical trial is unapproved, unregulated, and potentially unsafe. Compounding pharmacies are not permitted to make copies of a drug that has never been approved, and 'research-use' peptide sellers are not a lawful or safe source.

If you are looking for a weight-management medication today, FDA-approved options such as semaglutide and tirzepatide already exist and should be discussed with a licensed clinician. Survodutide, for now, is a drug to watch rather than one to take.

Availability outlook and timeline

The company has not disclosed a filing or launch date, so any timeline is an external estimate rather than a commitment. Independent trackers and analysts generally project that, if the broader SYNCHRONIZE program and safety database hold up, Boehringer Ingelheim could submit survodutide for obesity in late 2026 or 2027, with the earliest realistic FDA approval around 2028. The MASH indication runs on its own regulatory track and depends on the LIVERAGE outcome trials, which extend well beyond 2026.

Several catalysts remain outstanding: additional SYNCHRONIZE obesity readouts (including SYNCHRONIZE-2 in people with type 2 diabetes) expected during 2026, the pivotal LIVERAGE MASH data, and any formal regulatory submission. Until a filing is actually announced and a drug label exists, survodutide should be treated as a promising but unproven pipeline candidate. We will update this page as verified milestones are reported.